 CAMBRIDGE, Mass.--BUSINESS WIRE--Aura Biosciences Inc. NASDAQ: AURA, a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate VDC therapies for multiple oncology indications, today announced multiple presentations of data evaluating its first VDC, belzupacap sarotalocan AU-011, for the first-line treatment of patients with early-stage choroidal melanoma indeterminate lesions and small choroidal melanoma CM. The presentations include updated safety 